Researchers at Peking University have discovered that a filamentous gut fungus, Fusarium foetens, can reverse metabolic ...

Dr. Falk Pharma’s norucholic acid (NCA) drug has demonstrated potential in a Phase III trial for primary sclerosing ...

Dr. Falk Pharma, a research-based pharmaceutical company specializing in digestive and metabolic medicine, today announced ...

The primary analysis conducted after 96 weeks of treatment showed that NCA led to a statistically significant achievement of the trial’s primary endpoint, which was defined as partial normalisation of ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is ...

LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus ...

Here, we deployed a multidimensional approach to unravel the T-cell functional landscape in primary colorectal cancers (CRC) and liver metastases ... LA, FP and CD performed pathology analyses on ...

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant ...